LBA 2Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial. (13th May 2019) - Guarneri, V; Cinieri, S; Orlando, L; Bengala, C; Mariani, G; Bisagni, G; Frassoldati, A; Zamagni, C; Salvo, G De; Conte, P F